CSF antigliadin antibodies and the Ramsay Hunt syndrome
Citation Manager Formats
Make Comment
See Comments

Abstract
Although the association between celiac disease and progressive myoclonic ataxia is well recognized, in each of the reported cases the neurologic features began in middle adult life and usually in patients who had clinical or laboratory evidence of malabsorption. We report a case of progressive myoclonic ataxia and epilepsy (Ramsay Hunt syndrome) that began in childhood. In this patient there were no features suggestive of gluten intolerance. The presence of antigliadin antibodies in the serum and CSF suggested celiac disease was the cause of the patient's neurologic syndrome. Duodenal morphologic abnormalities reversed with treatment but no major changes were noted in the patient. Celiac disease should be considered in the differential diagnosis of myoclonic ataxia at any age, even in the absence of clinical evidence of gluten-sensitive enteropathy.
Neurologic disorders occur in approximately 8% of patients with celiac disease but their etiology remains uncertain.1 Encephalopathy, progressive multifocal leucomalacia, dementia, and epilepsy were described in association with gluten sensitivity2; and myelopathy, peripheral neuropathy, and myopathy were also reported in isolated cases.3
The association between celiac disease and myoclonus was reported on several occasions.1-8 In each of these individuals, the neurologic features began in middle adult life, often many years after the diagnosis and successful treatment of the gluten sensitivity.1,8 We describe a case of progressive myoclonus, ataxia, and epilepsy (the Ramsay Hunt syndrome) that began in childhood. Although the patient had no clinical, hematologic, or biochemical evidence of malabsorption, extensive investigations revealed both serologic and histologic evidence of celiac disease and the presence of antigliadin antibodies in the patient's CSF.
Case report. A 20-year-old woman was admitted for investigation of progressive disability and cognitive decline. She had a normal birth and development but at the age of 8 years her parents noted irregular jerking movements in both of her arms. During the subsequent 2 years, she had numerous absence episodes and one generalized tonic-clonic seizure while asleep. At the age of 11 years, her verbal IQ was 78 and her performance IQ was 60. Throughout her teenage years she became increasingly ataxic and from the age of 18 was confined to a wheelchair.
During the 18 months before our assessment, the patient's speech deteriorated, her cognitive function declined further, and she was no longer able to transfer from chair to bed unaided. Throughout this period she had maintained a good appetite for food, her weight had progressively increased, and she had no gastrointestinal symptoms nor any dermatologic complaints. There was no family history of neurologic disease or consanguinity. She was treated with clonazepam (2 mg tid) and sodium valproate (200 mg tid).
She was obese (80 kg, height 1.61 m) but general examination was otherwise unremarkable. She had spontaneous, stimulus-sensitive and action myoclonus. Cranial nerve examination was unremarkable apart from hypometric saccadic eye movements. Optic fundi were normal. She had a symmetric increase in tone in all four limbs but no weakness. Her reflexes were pathologically brisk but both plantar responses were flexor. She had marked truncal, appendicular, and gait ataxia, and cerebellar dysarthria. Formal psychometric analysis confirmed global cognitive impairment (IQ 50).
Clinical investigations including a full blood count, ESR, coagulation screen, urea and electrolytes, glucose, albumin, bone biochemistry, liver function tests, creatine kinase, and thyroid function tests were normal. She had a polyclonal elevation of the three major immunoglobin classes on serum electrophoresis (IgG 19.9 g/l, IgM 2.4 g/l, IgA 4.8 g/l).
Serum copper, ceruloplasmin, and 24-hour copper excretion were within the normal range, and vitamin E, B12, and folate levels were normal. After an 18-hour fast her blood lactate level was within the normal range. She had a normal urinary excretion of organic and amino acids and her blood acylcarnitines were normal. An EEG revealed slow wave bursts associated with small sharp waves and an evoked potential study revealed conduction delay in the central somatosensory pathways. Cranial MRI was normal. Her CSF opening pressure, glucose, protein, and cell count were normal and no oligoclonal bands were present. A muscle biopsy revealed normal morphology and histocytochemistry, and mitochondrial DNA analysis excluded the A8344G MERRF, A3243G MELAS, or 8993 NARP mutations in her blood and muscle. Histologic examination of a skin biopsy specimen was unremarkable.
A routine serum autoantibody screen was negative and anti-Purkinje cell antibodies were not detected. However, she had strongly positive titers for antigliadin IgA, IgG, and endomysial IgA. A duodenal biopsy revealed features typical of celiac disease with short, widened villi, crypt hyperplasia, and an inflammatory infiltrate in the lamina propria associated with increased numbers of intraepithelial lymphocytes (figure). Further CSF analysis revealed a polyclonal increase in IgG (0.075 g/l, 28% of total CSF protein) with no unmatched oligoclonal bands. Anti-Purkinje and anti-dorsal root ganglion antibodies were not present, but antigliadin IgA and IgG were detected in the CSF. The duodenal biopsy was repeated after 11 months on a gluten-free diet confirmed the diagnosis of celiac disease with the resolution of villous atrophy.
Figure. Histologic section of duodenum showing villous atrophy, crypt hyperplasia, a chronic inflammatory infiltrate in the lamina propria, and lymphoid cells infiltrating the surface epithelium. Final magnification ×750.
Discussion. This case illustrates two major points: first, the Ramsay Hunt syndrome can occur in association with celiac disease in the absence of any preceding clinical, hematologic, or biochemical features of malabsorption. Second, this neurologic syndrome can begin in childhood.
It is surprising our patient had normal cranial MRI. Although areas of high signal intensity on T2-weighted MRI in association with cerebellar atrophy were described in less severely affected patients with celiac disease,6,7 even in severe cases cranial imaging may be normal,7 as may the gross appearance of the brain at post mortem.5
The pathogenesis of the neurologic associations of celiac disease remains uncertain. Conventional biochemical indices of malabsorption may be within normal limits, and malabsorption of an unidentified factor may be responsible for the syndrome. However, in the majority of the reported cases myoclonus and ataxia developed in the presence of histologically normal small intestinal mucosa.1
Celiac disease in an immunologic disorder that is triggered by the ingestion of gliadin. An isolated vasculitis of the CNS was described in one patient with celiac disease; this responded to prednisolone and cyclophosphamide.9 In the absence of evidence to support a generalized breakdown of the blood-brain barrier, the presence of antigliadin antibodies in this patient's CSF would support an autoimmune etiology and the local production of antigliadin IgA and IgG within the CNS. Although these findings may have both diagnostic and pathophysiologic significance, the prevalence of CSF antigliadin antibodies in asymptomatic individuals with serum antigliadin antibodies is not known, and it is possible that they are an epiphenomenon.
Myoclonus and ataxia may begin up to 27 years after the initial diagnosis and successful treatment of the celiac disease. For this reason, we do not expect a major improvement in our patient's neurologic status on a gluten-free diet, but have modified her intake to reduce any subsequent risk of her developing intestinal neoplasia. Although immunosuppression with prednisolone, cyclophosphamide, or plasmapheresis have been tried in a number of patients, the results were not encouraging.1 We have not noted any objective change in her clinical signs after 10 months of this treatment, but her parents report improved concentration and a reduced nocturnal seizure frequency.
This case illustrates the diverse presentation of celiac disease and confirms that celiac disease should be considered in the differential diagnosis of myoclonus and ataxia, whatever the age of the patient and in the absence of any gastrointestinal signs.10 Antigliadin antibodies can be found in the serum of up to 12% of normal controls and 5% of patients with other specific neurologic syndromes.10 However, to our knowledge CSF antigliadin antibodies have not been documented before. Although their significance is uncertain at present, CSF antigliadin antibodies may have pathogenic significance and prove to be useful in identifying celiac disease in patients with unexplained ataxia and myoclonic epilepsy.
Footnotes
-
Received October 23, 1996. Accepted in final form May 2, 1997.
References
- 1.↵
Bhatia KP, Brown P, Gregory R, et al. Progressive myoclonic ataxia associated with coeliac disease. The myoclonus is of cortical origin, but the pathology is in the cerebellum. Brain 1995;118:1087-1093.
- 2.↵
Cooke WT, Smith WT. Neurological disorders associated with coeliac disease. Brain 1966;89:683-722.
- 3.↵
Finelli PF, McEntee WJ, Ambler M, Kestenbaum D. Adult celiac disease presenting as cerebellar syndrome. Neurology 1980;30:245-249.
- 4.
- 5.↵
Lu CS, Thompson PD, Quinn NP, Parkes JD, Marsden CD. Ramsey Hunt syndrome and coeliac disease: a new association? Mov Disord 1986;1:209-219.
- 6.↵
Brucke T, Kollegger H, Schmidbauer M, Muller C, Podreka I, Deecke L. Adult coeliac disease and brainstem encephalitis. J Neurol Neurosurg Psychiatry 1988;51:456-457.
- 7.↵
Tison F, Arne P, Henry P. Myoclonus and adult coeliac disease. J Neurol 1989;236:307-308.
- 8.
Mumford CJ, Fletcher NA, Ironside JW, Warlow CP. Progressive ataxia, focal seizures, and malabsorption in a 41 year old woman. J Neurol Neurosurg Psychiatry 1996;60:225-230.
- 9.↵
- 10.↵
Hadjivassiliou M, Gibson A, Davies-Jones GAB, Lobo AJ, Stephenson TJ, Milford-Ward A. Does cryptic gluten sensitivity play a part in neurological illness? Lancet 1996;347:369-371.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Editorials
Neurologic manifestations of celiac diseaseProven, or just a gut feeling?Anne H. Cross, Paul T. Golumbek et al.Neurology, May 27, 2003 -
Article
Transglutaminase 6 antibodies in the diagnosis of gluten ataxiaMarios Hadjivassiliou, Pascale Aeschlimann, David S. Sanders et al.Neurology, April 10, 2013 -
Articles
Autoantibody targeting of brain and intestinal transglutaminase in gluten ataxiaM. Hadjivassiliou, M. Mäki, D. S. Sanders et al.Neurology, February 13, 2006 -
Article
Effect of gluten-free diet on cerebellar MR spectroscopy in gluten ataxiaMarios Hadjivassiliou, Richard A. Grünewald, David S. Sanders et al.Neurology, July 19, 2017